Short answer
MANNKIND CORP (MNKD) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $102M (up 24.0% year over year) with net income of −$23M.
Q3 2026 key financials · XBRL
- Revenue
- $102M
- +24.0% YoY · −6.9% QoQ
- Net income
- −$23M
- −390.8% YoY · −22.0% QoQ
- Operating margin
- -2.1%
- EPS (diluted)
- −$0.07
- −333.3% YoY · +0.0% QoQ
Source: XBRL data from the MANNKIND CORP (MNKD) Q3 2026 10-Q on SEC EDGAR. USD.
MANNKIND CORP Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $101.9M, up $19.7M YoY from $82.1M
- Commercial product sales $45.0M, up $22.7M YoY, led by Furoscix net revenue $22.4M
- Commercial product gross margin decreased 5% YoY, primarily from lower-margin Furoscix on-body infusor
- Operating cash use $58.3M through nine months, versus $26.2M generated YoY
- Capital resources $96.6M; $49.8M private-placement proceeds funded $44.8M CVR payment
- Near-term liquidity covered at least 12 months; tariff-related sourcing costs and Furoscix ReadyFlow adoption remained headwinds
Risk Factors
- New competitive risk: United Therapeutics’ February 2026 Tresmi plans could divert emphasis from Tyvaso DPI and materially reduce MannKind royalties
- New international trade risk: recently announced tariffs could raise costs for up to 36 months before contract repricing
- Regulatory risk: OBBBA reduced insurance coverage and Medicaid enrollment, potentially lowering demand and reimbursement for commercial products
- Operational risk: Yutrepia launched in June 2025, creating direct competition with Tyvaso DPI for treprostinil market share
- Financial risk: Blackstone Credit Facility requires at least $40.0 million quarterly liquidity and restricts additional debt, acquisitions, and asset sales
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other MANNKIND CORP quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.